STAT1h
Pharmalittle: We’re reading about NIH directors on leave, a shaky start for the FDA commish, and more
Directors of five NIH institutes have been placed on administrative leave or offered new assignments as part of sweeping HHS ...
‘Ravenousness was in my job description.’ What happens when a food writer goes on a weight-loss drug?
For a variety of reasons, Globe Food contributor Kara Baskin took the leap and started Zepbound. But first she worried: "What ...
Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform
Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co. Zepbound and generic ...
‘Don’t Fall for the Hype,’ Says Top Analyst about HIMS’ Decision to Sell Zepbound
Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli ...
Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform
Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...
Hims & Hers shares rise as company adds new weight-loss medications to platform
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...
Finbold2d
2 healthcare stocks to buy ahead of Trump’s pharmaceutical tariffs
While tariffs have triggered market volatility, certain pharmaceutical stocks still present strong investment opportunities.
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...